Tg Therapeutics (TGTX) EBITDA Margin (2017 - 2026)
Tg Therapeutics' (TGTX) quarterly EBITDA Margin came in at 16.98% in Q1 2026, up 985.0% year-on-year from 1.56% in Q1 2025, and down 35.24% quarter-over-quarter from 26.22% in Q4 2025.
Tg Therapeutics (TGTX) EBITDA Margin (2017 - 2026) Analysis & Trends
Tg Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 16.98% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 985.0% year-over-year to 16.98% in Q1 2026; TTM through Mar 2026 was 21.35%, a 586.0% increase from a year earlier, with the FY2025 full-year figure at 20.01%, up 727.0% from the prior year.
- EBITDA Margin declined to 16.98% in Q1 2026 per TGTX's latest filing, from 26.22% in the prior quarter.
- Across five years, EBITDA Margin topped out at 69.22% in Q3 2023 and bottomed at 96923.75% in Q4 2022.
- The 5-year median for EBITDA Margin is 7.13% (2025), against an average of 8504.08%.
- Across the five-year window, EBITDA Margin slumped 9291914 bps in 2022 and surged 9689536 bps in 2023, its largest moves.
- Year by year, EBITDA Margin stood at 96923.75% in 2022, then jumped by 100 bps to 28.39% in 2023, then surged by 197 bps to 27.68% in 2024, then fell by 5 bps to 26.22% in 2025, then slumped by 35 bps to 16.98% in 2026.
- Per Business Quant, the three latest TGTX EBITDA Margin figures stand at 16.98% (Q1 2026), 26.22% (Q4 2025), and 18.16% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tg Therapeutics | 8.88 Bn | 8.80 Bn | 171.41 Mn | 16.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.98% |
| Dec 31, 2025 | 26.22% |
| Sep 30, 2025 | 18.16% |
| Jun 30, 2025 | 24.69% |
| Mar 31, 2025 | 7.13% |
| Dec 31, 2024 | 27.68% |
| Sep 30, 2024 | 14.82% |
| Jun 30, 2024 | 12.00% |
| Mar 31, 2024 | -14.60% |
| Dec 31, 2023 | -28.39% |
| Sep 30, 2023 | 69.22% |
| Jun 30, 2023 | -277.93% |
| Mar 31, 2023 | -474.07% |
| Dec 31, 2022 | -96,923.75% |
| Sep 30, 2022 | -37,194.68% |
| Jun 30, 2022 | -6,555.72% |
| Mar 31, 2022 | -3,317.06% |
| Dec 31, 2021 | -4,004.61% |
| Sep 30, 2021 | -4,193.50% |
| Jun 30, 2021 | -5,015.66% |